New Breakthrough Treatment for Age Related Macular Degeneration Offers Hope for Restoring Vision

Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, the part of the retina responsible for sharp central vision. AMD is most commonly found in people over the age of 50, and is the leading cause of blindness in older adults.

There are two forms of AMD: dry and wet. Dry AMD is the most common form and is characterized by the gradual breakdown of the macular tissue, leading to the formation of small, yellowish deposits called drusen. Wet AMD, although less common, is more severe and involves the growth of abnormal blood vessels beneath the retina, which can leak and cause scarring.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭:https://www.alliedmarketresearch.com/request-toc-and-sample/3538

Risk factors for AMD include age, family history, smoking, high blood pressure, high cholesterol, and a diet lacking in nutrients such as vitamin C, E, and zinc. Symptoms may include blurred or distorted vision, blind spots, or difficulty seeing fine details.

Treatment for AMD may include lifestyle changes such as quitting smoking and adopting a healthy diet, as well as the use of certain vitamins and supplements. In some cases, medications or laser therapy may be used to prevent the growth of abnormal blood vessels in wet AMD. However, there is currently no cure for AMD, and early detection and management is crucial in preserving vision.

𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

1. Bayer HealthCare
2. F. HoffmannLa Roche
3. Regeneron Pharmaceuticals
4. Novartis AG
5. Valeant Pharmaceuticals International
6. Pfizer
7. Acucela Inc.
8. GlaxoSmithKline plc
9. Alimera Sciences
10. Allergan

 𝐀𝐠𝐞 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 (𝐀𝐌𝐃) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

The Age Related Macular Degeneration (AMD) market is a growing segment in the healthcare industry, with an increasing number of people being diagnosed with AMD every year. AMD is a major cause of visual impairment and blindness in older adults, and there is a significant need for effective treatments.

The market is segmented into two types: Wet AMD and Dry AMD. Wet AMD is characterized by the growth of abnormal blood vessels beneath the retina, which can cause bleeding and scarring. Dry AMD, on the other hand, is characterized by the gradual breakdown of the macular tissue, leading to the formation of small, yellowish deposits called drusen.

The major drugs used to treat AMD include Lucentis, Eylea, Avastin, and others. These drugs are administered either intravenously or via intravitreal injection. Lucentis and Eylea are both FDA-approved for the treatment of Wet AMD, while Avastin is used off-label for the same indication. All three drugs work by inhibiting the growth of new blood vessels in the eye.

The market for AMD drugs is expected to grow due to the increasing prevalence of AMD in the aging population. However, the high cost of treatment may be a barrier to access for some patients. In addition, there is ongoing research and development aimed at developing new treatments for AMD, including gene therapy and stem cell therapy.

In terms of market share, Lucentis and Eylea are the two leading drugs used to treat Wet AMD. Lucentis was the first drug approved for this indication, and it has been widely used since its approval in 2006. Eylea, which was approved in 2011, has gained popularity due to its longer duration of action and fewer injections required compared to Lucentis.

Avastin, which is a less expensive alternative to Lucentis, is also used off-label for the treatment of Wet AMD. However, there are concerns about its safety and efficacy compared to Lucentis and Eylea.

In conclusion, the AMD market is a growing segment in the healthcare industry, driven by the increasing prevalence of AMD in the aging population. Lucentis, Eylea, and Avastin are the major drugs used to treat Wet AMD, and ongoing research and development efforts are aimed at developing new treatments for AMD. The high cost of treatment may be a barrier to access for some patients, and there is a need for more affordable treatment options.

𝐈𝐧𝐪𝐮𝐢𝐫𝐲 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞: https://www.alliedmarketresearch.com/purchase-enquiry/3538

𝐓𝐡𝐞 𝐀𝐠𝐞 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 (𝐀𝐌𝐃) 𝐦𝐚𝐫𝐤𝐞𝐭 𝐜𝐚𝐧 𝐚𝐥𝐬𝐨 𝐛𝐞 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐛𝐲 𝐫𝐞𝐠𝐢𝐨𝐧 𝐢𝐧𝐭𝐨 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚, 𝐄𝐮𝐫𝐨𝐩𝐞, 𝐀𝐬𝐢𝐚-𝐏𝐚𝐜𝐢𝐟𝐢𝐜, 𝐚𝐧𝐝 𝐋𝐀𝐌𝐄𝐀.

North America includes the United States, Canada, and Mexico. This region is expected to dominate the market due to the high prevalence of AMD in the aging population, as well as the availability of advanced healthcare infrastructure and technology.

Europe includes France, Germany, Italy, Spain, the UK, and the rest of Europe. The market in Europe is also expected to grow due to the increasing prevalence of AMD in the aging population, as well as the increasing adoption of advanced treatments and therapies.

Asia-Pacific includes China, Japan, India, South Korea, Australia, and the rest of Asia-Pacific. The market in this region is expected to grow rapidly due to the increasing awareness of AMD and the growing healthcare infrastructure in developing countries.

LAMEA includes Brazil, South Africa, Saudi Arabia, and the rest of LAMEA. This region is expected to have a smaller market share due to the lower prevalence of AMD in these countries and the limited availability of advanced healthcare infrastructure.

𝐁𝐮𝐲 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐀𝐠𝐞 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 (𝐀𝐌𝐃) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭: https://www.alliedmarketresearch.com/checkout-final/0438b8aee4bd251ce98598127f475374

𝐁𝐫𝐨𝐰𝐬𝐞 𝐨𝐭𝐡𝐞𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Pharmaceutical Excipients Market https://www.alliedmarketresearch.com/pharmaceutical-excipients-market

Interventional Cardiology and Peripheral Vascular Devices Market https://www.alliedmarketresearch.com/Interventional-Cardiology-and-Peripheral-Vascular-Devices-market

Asia-Pacific Medical Nonwoven Disposables Market https://www.alliedmarketresearch.com/asia-pacific-medical-nonwoven-disposables-market

Extremity Reconstruction Market https://www.alliedmarketresearch.com/extremity-reconstruction-market

Remote Patient Monitoring Market https://www.alliedmarketresearch.com/remote-patient-monitoring-market

Protein Labeling Market https://www.alliedmarketresearch.com/protein-labeling-market

Vaccines Market https://www.alliedmarketresearch.com/vaccines-market

Dental Consumables Market https://www.alliedmarketresearch.com/dental-consumables-market

Sports Medicine Market https://www.alliedmarketresearch.com/Sports-Medicine-market

Breast Biopsy Market https://www.alliedmarketresearch.com/Breast-Biopsy-market

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.